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In this study, we tested the hypothesis that single nucleotide polymorphisms (SNPs) of differentiation-associated
human gene icb-1 (C1orf38) may be associated with ovarian cancer susceptibility. For this purpose, we compared the
genotype and allele frequencies of the SNPs rs1467465 and rs12048235 in a group of 184 ovarian cancer patients
with a control group of 184 age- and gender-matched women without any malignancy. Genotype-phenotype
association revealed that A allele of SNP rs1467465 was more frequent in ovarian cancer patients than in the
control group (0.40 vs. 0.33, OR 1.37, 95% CI 1.013-1.853, p = 0.04). After analysis of allele positivity we observed
that A-positive genotypes were more frequent in the ovarian cancer group (0.65 vs. 0.53, OR 1.63, 95% CI
1.072-2.483, p = 0.02). Furthermore, the heterozygous genotype of rs1467465 was found to be more frequent
in the patients group (0.50 vs. 0.41, OR 1.63, 95% CI 1.045-2.045, p = 0.03). No significant results were obtained with
regard to SNP rs1204823. Our data suggest, that SNP rs1467465 of human gene icb-1 might affect susceptibility to
ovarian cancer.
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Ovarian cancer is the most lethal gynecological malig-
nancy and the sixth most common cancer among
women in industrialized countries [1]. Because of its po-
tential for aggressive local invasion and the lack of sensi-
tive early screening methods, around 75% of all ovarian
cancers are diagnosed at an advanced stage. Despite ex-
tensive research during the last decades, the etiology and
pathogenesis of this tumor entity is only partly under-
stood. Binding of steroid hormones like estrogens to
their receptors like estrogen receptor α (ERα) is known to
stimulate growth of ovarian cancer cells [2,3]. Recently we
reported interaction between ERα and differentiation-
associated gene icb-1 (Themis2, C1orf38) in ovarian cells
[4,5]. Icb-1 is a vertebrate gene located on human chromo-
some 1 (1p35.3), which was identified and cloned by our
group in an attempt to analyze gene expression changes
during in vitro differentiation of endometrial tumor cells
[6]. Recent studies suggested icb-1 to act as a tumor* Correspondence: otreeck@caritasstjosef.de
1Department of Gynecology and Obstetrics, University Medical Center
Regensburg, Regensburg, Germany
Full list of author information is available at the end of the article
© 2014 Schüler et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.suppressor in ovarian cancer - its knockdown accelerated
growth of various ovarian cancer cell lines and led to up-
regulation of ovarian cancer markers like CLDN16 and
KLK10 [7]. Icb-1 seems to suppress progression of ovarian
cancer by inhibition of oncogenic pathways activated by
ERα. Thus, the individual level of icb-1expression, which
can be assumed to result from different epigenetical, but
also genetical factors like single nucleotide polymorphisms
(SNPs), might affect ovarian cancer risk.
Today, only 5–10% of ovarian cancer cases have been
shown to be hereditary [8]. However, further polymor-
phisms in crucial genes are expected to affect susceptibility
to ovarian cancer [9]. Single nucleotide polymorphisms
(SNPs) are the most frequent sequence variations in the
human genome. SNPs located in exon regions may alter
protein function, whereas SNPs in the gene promoter
can modify gene expression levels [9-15]. In the last
years, a multitude of genotype-phenotype association
studies have been published examining the significance of
randomly chosen SNPs in different hormone-dependent
diseases [12,16-20].
To test the relevance of two SNPs of icb-1 gene for
susceptibility to ovarian cancer, we genotyped 184 womenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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malignancy.
Patients and methods
Patients
In this study we used blood samples from 184 Caucasian
women with sporadic ovarian cancer and a median age
at diagnosis of 60.7. The gender-matched control group
contained the same number of Caucasian women without
any malignancy at the beginning of the study and a median
age at inclusion of 60.8. We included ovarian cancer blood
samples collected in the Department of Gynecology and
Obstetrics of the University of Regensburg, serum samples
from the Department of Gynecology and Obstetrics of the
University of Tübingen, Germany and further blood sam-
ples from the Second Department of Gynecology of the
University School of Medicine of Lublin, Poland. Gen-
erally, Caucasian women with sporadic ovarian cancer
and available information on grading, stage, and histo-
logical subtype from 2002 to 2012 were included. The
histopathological characteristics of the patients are shown
in Table 1. The retrospective study was approved by the in-
stitutional review board “Ethikkommission der Universität
Regensburg and by the Institutional Review Boards of the
Universities Tübingen and Lublin”.
SNP analysis
SNPs in the icb-1 gene were selected using the internet web
sites www.genecards.org. and http://www.ncbi.nlm.nih.gov/Table 1 Staging and histopathological characteristics of
ovarian cancer cases (n = 184)
Characteristics Patient numbers
FIGO staging
Stage I 38
Stage II 13
Stage III 89
Stage IV 37
unknown 7
Histological subtype
serous 126
endometrioid 36
mucinous 17
clear cell 7
transitional cell 2
undifferentiated 8
Histological grade
G1 24
G2 49
G3 111SNP. Intronic polymorphism rs1467465 is located at pos-
ition 28083990 of chromosome 1, between icb-1 exons 4
and 5 and rs12048235 is located at position 28078471 of the
same chromosome, in the intron between exons 2 and 3.
Genomic DNA was isolated from 100 μl EDTA-blood
after addition of 300 μl of lysis buffer (1% v/v TritonX,
0.32 M Sucrose, 0.01 M Tris (pH 7.5) and 5 mM MgCl2)
and two-fold centrifugation (13000 g) for 30 seconds. Pellet
was resuspended in 50 μl PCR buffer (GoTaq buffer,
Promega, Madison, USA) containing 0.5% Tween 20
and 10 mAnson units proteinase K (Merck, Darmstadt,
Germany) followed by incubation at 50°C over night and fi-
nally heat inactivation of the enzyme for 10 min at 95°C.
The genomic DNA-containing lysate was subjected to a
tetra-primer ARMS PCR approach [10] allowing allele-
specific amplification using the PCR primers listed in
Table 2 (synthesized at Metabion, Martinsried, Germany).
For this purpose, to 100 ng of genomic DNA, 2 μl of 5 x
GoTaq buffer, 0.2 μl of dNTP Mix (10 mM) (Fermentas, St.
Leon-Rot, Germany), 0.2 μl of each PCR primer (10 μM)
and 0.5 units GoTaq polymerase (Promega, Madison, USA)
was added and PCR reaction was carried out using a
Biometra T1 thermocycler (Goettingen, Germany). PCR
program was 10 min 94°C followed by 38 PCR cycles of
94°C (30 sec), 56°C (30 sec) and 72°C (60 sec), followed by
a final extension for 5 min step at 72°C. PCR products were
analysed by means of 1.5% agarose gelelectrophoresis.
Statistical analysis
Deviation from the Hardy-Weinberg equilibrium was es-
timated by the Fisher’s exact test and the χ2 test, and all
values were subjected to one-way ANOVA to achieve
homogeneity of variance. Statistical tests for association
(C.I.: 95% confidence interval) and for significance were
carried out using SPSS for Windows 8.0 (SPSS, Inc.,
Chicago, IL). P < 0.01 was considered statistically signifi-
cant. After tests for deviation from Hardy-Weinberg equi-
librium were conducted, allele frequency, allele positiviy
and genotype frequencies were determined. Odds ratio
(OR) was calculated using the more frequent homozygous
genotypes as reference group.Table 2 PCR primers used for SNP analysis
Polymorphism Primer Sequence
rs1467465 IP1 GCAGACGTCATGTAGCATCTGGCCCA
IP2 GAAAGAGGACTTCCATTGCGTTCCCCAAC
OP1 AGGGAGCTGTGCCGCACACTCTGTAAAG
OP2 GGAGACAGGGTGTTCCTGGGATTTTCCA
rs12048235 IP1 GAAGTCTAGTGTGTCTGTCAGGGAATTTG
IP2 ACCAGAGACACAGAGAATGGAAGAGGTAT
OP1 GGAGGAAAGGCTAAGATGGCAGTTAG
OP2 ATGACAGATTTGCATCTGGACATCTG
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Genotype analysis
After genotyping of 184 ovarian cancer patients and
such as many women without any malignancy, we ob-
served a higher frequency of heterozygous AG genotype
of the icb-1 gene SNP rs1467465 in the patients group.
Genotype-phenotype association suggested that the het-
erozygous genotype of rs1467465 could be a risk factor
for the development of ovarian cancer (OR 1.63, 95% CI
1.045-2.045, p = 0.03) (Table 3). The frequency of the
homozygous genotypes did not differ significantly be-
tween both groups in this study. Moreover, no significant
differences between healthy women and women with ovar-
ian cancer were found for the heterozygous/homozygous
frequencies of the icb-1 gene SNP rs12048235 in this study
(Table 3).
Allele frequency
When we analysed the allele frequencies of the icb-1
gene SNPs we found that in women with ovarian cancer
the A allele of SNP rs1467465 was carried significantly
more often than in women without an ovarian malignancy
(0.40 vs. 0.33, OR 1.37, 95% CI 1.013-1-853, p = 0.04)
(Table 3). Ovarian cancer patients exhibited significantly
less G-positive alleles of this SNP. We were not able to
show any significant differences between healthy women
and women with ovarian cancer in the allele positivity ana-
lysis of the icb-1 gene SNP rs12048235 (Table 3).
Allele positivity
Phenotype-genotype association analyses of allele posi-
tivity of the icb-1 gene SNPs revealed that A allele posi-
tivity of SNP rs1467465 was more frequent in patientsTable 3 Comparison of SNP genotypes between ovarian canc
rs1467465 Genotype frequency
GG AA AG
Cases 0.35 0.15 0.50
Controls 0.47 0.13 0.41
P 0.13 0.03
OR n.s. 1.63
C.I. 95 % n.s. 1.045-2.045
rs12048235 Genotype frequency
GG AA AG
Cases 0.42 0.12 0.46
Controls 0.42 0.15 0.45
P 0.48 0.87
OR n.s. n.s.
C.I. 95 % n.s. n.s.
After tests for deviation from Hardy-Weinberg equilibrium were conducted, allele fr
ratio (OR) was calculated using the more frequent homozygous genotypes as refere
n.s.=not significant.with ovarian cancer than in the control group of healthy
women (0.65 vs. 0.53, OR 1.632, 95% CI 1.072-2.483,
p = 0.02) (Table 3). G positive alleles were less exhibited in
patients with ovarian cancer. We did not find any signifi-
cant difference between healthy women and women with
ovarian cancer in allele positivity analyses of the icb-1 gene
SNP rs12048235 (Table 3).
Discussion
Our data suggest SNP rs467465 in icb-1 gene to affect
susceptibility to ovarian cancer. The vertebrate gene icb-1
previously has been shown to inhibit growth of ovarian
cancer cells in vitro and to suppress expression of ovarian
cancer biomarkers like kallikrein-related peptidase 10 and
claudin 16 or other cancer-related genes activated by estro-
gens or TNFα [7]. Furthermore, knockdown of icb-1 was
shown to inhibit induction of differentiation-associated
genes like E-cadherin triggered by vitamin D3 or all-trans
retinoic acid. Loss of icb-1 expression previously was suffi-
cient to transform the estrogen-unresponsive ovarian can-
cer cell line SK-OV-3 into a line exhibiting a strong
proliferative response to estrogen stimuli [5]. Icb-1 gene
contains an imperfect estrogen response element (ERE)
and transcript levels of icb-1 were shown to be estrogen-
responsive in ovarian cancer cells in an estrogen receptor α
(ERα)-dependent manner [4]. Estrogens are able to pro-
mote ovarian tumor progression [21], which is associated
with loss of cellular differentiation. Thus, women carrying
the minor frequent allele or genotype of SNP rs1467465,
which might lead to decreased icb-1 function, are sug-
gested to be less sensitive to the antitumoral effects of vita-
min D3 and all-trans retinoic acid, but more sensitive to
the oncogenic effects triggered by estrogens or TNFα.er patients and women without any malignancy
Allele frequency Allele positivity
G A G A
0.60 0.40 0.85 0.65
0.67 0.33 0.88 0.53
0.04 0.02
1.37 1.632
1.013-1.853 1.072-2.483
Allele frequency Allele positivity
G A G A
0.65 0.35 0.88 0.58
0.63 0.37 0.85 0.59
0.61 0.90
n.s. n.s.
n.s. n.s.
equency, allele positivity and genotype frequencies were determined. Odds
nce group. Bold p-values were considered to be statistically significant.
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without clear functional relevance, because icb-1 gene
does not exhibit SNPs in exons or in transcription factor
binding sites. Numerous studies reported an association
between intronic SNPs and disease risk [22-24]. Intronic
SNPs could affect intronic splicing enhancer or silencer
signals and thereby modulate the expression of different
splice variants [25]. This report is the first one ana-
lysing the association of icb-1 gene SNPs rs1467465 and
rs12048235 with ovarian cancer risk. Recently, we were
able to show that the SNP rs1467465 might affect breast
cancer susceptibility, which might corroborate the data
presented here [26]. The results of the genotype-phenotype
association study we performed clearly demonstrated that
the heterozygous genotype of SNP rs1467465, the A-allele
and A-positive genotypes were more frequent in ovarian
cancer patients and thus might be risk factors for this dis-
ease. The general low odds ratios reveal that the effects of
the gene polymorphism are low, as expected from a com-
plex etiology.
Taken together, the results of this study suggest that a
SNP in human icb-1 gene might be able to affect suscep-
tibility to ovarian cancer. Our data encourage further
studies examining the relevance of icb-1 gene in ovarian
cancer and combining analysis of rs467465 with other
polymorphisms affecting ovarian cancer risk.
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